Analysis
PublicOLOGY BIOSERVICES, INC. holds $17.9M across 7 federal awards, concentrated at Department of Defense (DOD). Set-aside status: NONE.
Contract facts
NONETHIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO BOTULINUM TOXIN.
Incumbent footprint
Public recordOLOGY BIOSERVICES, INC. — $17.9M obligated across 7 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open OLOGY BIOSERVICES, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract W911SR22D0009?
W911SR22D0009 (THIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO BOTULINUM TOXIN.) is a Department of Defense (DOD) award with an estimated value of —, currently held by OLOGY BIOSERVICES, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on W911SR22D0009?
OLOGY BIOSERVICES, INC. is the incumbent with $17.9M across 7 related awards in SCOUT’s public footprint.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →